PET-CT improves care of limited-stage small-cell lung cancer patients

June 25, 2013

Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer is only present in one lung, but may have spread to lymph nodes or tissue between the lungs. These patients are often treated with chemotherapy and definitive radiation therapy. Staging information is essential because of the high propensity for metastatic disease in SCLC, and the identification of metastases can spare patients from the toxicity associated with thoracic radiotherapy. Furthermore, in those patients who do receive radiotherapy, knowing the exact extent of disease may permit more accurate treatment volume delineation.

Until 2011, the National Comprehensive Cancer Network (NCCN) recommended a bone scan as part of the initial evaluation of all newly diagnosed SCLC patients. However, in 2012, the NCCN began recommending positron emission tomography computed tomography (PET-CT) in lieu of bone scan. Researchers from the University of Pennsylvania wanted to know the clinical impact of using PET instead.

A study published in the July issue of the Journal of Thoracic Oncology (JTO), concludes that PET-CT improves staging accuracy and intrathoracic disease identification, which translates into an improvement in clinical outcome in these patients.

"Pretreatment PET staging of LS-SCLC was associated with improved survival," the authors report. "PET-staged had an improved 3-year overall survival from diagnosis (47 percent versus 19 percent; p-.03) compared with those with LS-SCLC who were not staged with PET." The lead author of this work is Dr. Eric Xanthopoulos. IASLC co-authors include Dr. Corey Langer, Dr. Charles Simone and Dr. Ramesh Rengan.

Related Stories

Life expectancy prolonged for esophageal cancer patients

June 4, 2012

For those with esophageal cancer, initial staging of the disease is of particular importance as it determines whether to opt for a curative treatment or palliative treatment. Research presented in the June issue of The Journal ...

Bone marrow biopsy adds little to PET/CT staging of Hodgkin's

November 15, 2012

(HealthDay)—For patients with treatment-naive Hodgkin's lymphoma (HL) staged using [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT), routine bone marrow biopsy (BMB) has little or no therapeutic ...

PET/MR effective for imaging recurrent prostate cancer

June 11, 2013

When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to ...

Recommended for you

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.